Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

KERNX Health vs YourHealthRx

KERNX Health
Graded #276

Lower grade

vs+7.3999999999999915
YourHealthRx
Graded #119

Higher grade

The verdict

YourHealthRx takes it — 69.6/100 to 62.2/100.

YourHealthRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. YourHealthRx is a scientist-founded peptide and GLP-1 telehealth platform available in all 50 states and DC via a multi-state (IMLC) clinician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKERNX Health +9
62
53
Dose & formulationYourHealthRx +11
64
75
Clinical oversightYourHealthRx +16
71
87
Labs & monitoringYourHealthRx +15
52
67
FulfillmentYourHealthRx +25
69
94
Contract termsKERNX Health +12
45
33
KERNX Health · left barYourHealthRx · right bar

The numbers

MetricKERNX HealthYourHealthRx
WeighScore62.2/10069.6/100
GradeCC
Scorecard rank#276#119
Semaglutide$129/mo (promotional rate, plus a separate fee, compounded)$170/mo (compounded)
Tirzepatide$199/mo (promotional rate, plus a separate fee, compounded)$210/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
KERNX Health

Graded #276 · C

Strengths

  • Publishes plan pricing openly, before any intake or account creation
  • Month-to-month with no long-term contract and no multi-month prepayment
  • Billing starts only after a licensed provider approves treatment
  • LegitScript certification verified against the issued seal, not just the badge

Where it loses points

  • Its own pricing page contradicts itself: it claims no separate consultation charges, then states a $25-$60 fee applies per visit
  • The consultation fee is charged whether or not a prescription is issued
  • Advertised $129 and $199 rates are time-limited founding rates; standard rates are $249 and $299
  • No compounding pharmacy is named anywhere on the site
  • Shipping claims conflict: a 48-hour figure on the homepage against 1-2 days to ship plus 2-3 days transit in the FAQ
YourHealthRx

Graded #119 · C

Strengths

  • Available in all 50 states and DC through a multi-state (IMLC) licensed clinician network
  • Compounded semaglutide and tirzepatide in two formats - weekly injectable (with B12) or daily oral dissolving tablet
  • Flat subscription price that doesn't change as your dose increases (no titration penalty)
  • Science-forward, clinician-led, with built-in follow-up, lab testing, and a broad peptide and longevity catalog (BPC-157, TB-500, sermorelin, NAD+)
  • Transparent, education-first positioning with published medical disclaimer, privacy, and terms

Where it loses points

  • Eligibility and prescribing run through partner clinical workflows - YourHealthRx is the platform, not the prescriber or pharmacy
  • Compounded medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named ('transparent sourcing' claimed but no pharmacy disclosed)
  • Headline prices include a first-month intro rate; ongoing monthly cost is higher (semaglutide ~$170, tirzepatide ~$210)
  • No LegitScript certification displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard